CureVac’s Final Chapter: The Path to Delisting and Shareholder Payout

The curtain is closing on CureVac's tenure as a publicly traded entity. Following its acquisition by fellow mRNA specialist BioNTech, the company's stock market narrative has shifted entirely. Investor focus is no longer on clinical trial results or pipeline updates, but on the final administrative steps that will culminate in its removal from the exchange. For remaining shareholders, understanding the imminent "squeeze-out" procedure is now the paramount concern.

The coming weeks are purely about executing the transaction's final phase. BioNTech, having secured approximately 86.75% of CureVac's shares, is initiating the formal process to compel the remaining minority shareholders to sell their holdings. This compulsory acquisition, known as a squeeze-out, is scheduled for completion during January 2026.

This process directly impacts investment portfolios. As the permanent delisting from public trading approaches, the stock's liquidity is expected to evaporate. Its share price is no longer influenced by company operations or news; instead, it is effectively pegged to the takeover terms and the anticipated cash compensation per share. The era of speculating on breakthroughs from CureVac's proprietary mRNA pipeline is over, as those assets are now integrated into BioNTech's portfolio.

Should investors sell immediately? Or is it worth buying CureVac?

Trading Activity in the Final Stages

Despite the predetermined outcome, the stock saw notable movement as the latest trading week concluded. On Friday, shares advanced by 2.86 percent to $4.67. While this move pushed the price above some short-term technical averages, market observers largely dismiss it as a traditional bullish signal given the extraordinary circumstances.

Analysts attribute these price fluctuations to arbitrage trading and final portfolio adjustments by institutional investors ahead of the settlement. No fundamental re-rating of the company is occurring. The investment thesis is now defined by a capped risk profile, with both downside risk and upside potential largely constrained by the fixed acquisition terms.

The Final Countdown

For shareholders, the remaining trading days are merely a technical prelude to the final payout. All that remains is the administrative execution of the squeeze-out, leading to the disbursement of the agreed cash settlement. The story of CureVac as a standalone stock is concluding, with its future now a subsidiary chapter within the BioNTech narrative.